Marizomib

Drug Profile

Marizomib

Alternative Names: NPI-0052; Salinosporamide A

Latest Information Update: 31 Jan 2017

Price : $50

At a glance

  • Originator Nereus Pharmaceuticals
  • Developer Celgene Corporation; Triphase Accelerator Corporation
  • Class Anti-inflammatories; Antineoplastics; Lactones; Pyrroles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase I/II Glioblastoma
  • Preclinical Cancer
  • No development reported Lymphoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 18 Nov 2016 Updated efficacy and adverse events data from a phase I/II trial in Glioblastoma released by Triphase Accelerator Corporation
  • 17 Nov 2016 Celgene Corporation acquires marizomib from Triphase Accelerator Corporation
  • 01 Aug 2016 Phase-I clinical trials in Glioblastoma (Newly diagnosed, Combination therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT02903069; 9207423)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top